Theralase Technologies Inc. announced that Virginia Urology has received site Institutional Review Board approval to commence a pivotal phase II Non-Muscle Invasive Bladder Cancer Clinical Study to enroll and treat patients with Bacillus Calmette Guerin-Unresponsive Carcinoma In-Situ or are intolerant to BCG Therapy. The company has central IRB approval to launch a number of US clinical sites, subject to local site IRB approval. VU is the first site to receive both central and local site IRB approval. There are 5 additional US clinical study sites that have received central IRB approval and are expected to receive local IRB approval in first quarter 2021. VU has a long history of providing quality care to the Greater Richmond area since 1929. VU is comprised of 6 locations throughout the Greater Richmond area with over 55 board-certified physicians that span nearly every discipline within the field of urology. Because VU consists of diverse medical professionals, they are able to provide the latest technologies with a mission of providing the best possible care for each patient. To date 14 patients have been treated in Study II. With the addition of VU, the Company now has 5 clinical study sites open in Canada and 1 in the US for patient enrollment and treatment.